LabCorp (NYSE:LH) has launched a new test designed to assess the capacity of antibodies in plasma to inhibit the SARS-CoV-2 virus. It says the assay can be used in the development of a COVID-19 vaccine and in screening convalescent plasma for prophylactic and therapeutic use.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.